Log inSign up
Sanofi
7,343 posts
user avatar
Sanofi
@sanofi
An R&D driven, AI-powered biopharma company committed to improving lives and delivering compelling growth. Terms for interactions: bit.ly/sanofi-terms
Paris
sanofi.com
Joined April 2009
216
Following
145.7K
Followers
  • user avatar
    Sanofi
    @sanofi
    29m
    What a start at #VivaTech! Visit us at Booth 1D01 through June 20 to experience how we’re reinventing AI across the value chain. Learn more: sanofi.com/en/magazine/ai… #Sanofi @VivaTech
    00:00
    114
  • user avatar
    Sanofi
    @sanofi
    Jun 15
    We’re back at #VivaTech 2026, and we’re raising the bar on what AI can do for global health. Visit us June 17 – 20 at Booth 1D01 to see how our teams are accelerating breakthroughs across everything from research and development to manufacturing and supply, driving faster,
    751
  • user avatar
    Sanofi
    @sanofi
    Jun 12
    The @US_FDA granted accelerated approval for a treatment for #Type1Diabetes. Learn more: spkl.io/60117DB2R
    Breaking News FDA grants accelerated approval to a T1D treatment is centered on a white circle with a blurred purple cellular background. A black 'S' logo with a purple dot is at the bottom.
    1K
  • user avatar
    Sanofi
    @sanofi
    Jun 10
    #NEWS: Update on our phase 3 clinical study in chronic inflammatory demyelinating polyneuropathy (CIDP). Learn more ⬇️ sanofi.com/en/media-room/…
    Update on our phase 3 clinical study MOBILIZE for our investigational treatment in chronic inflammatory demyelinating polyneuropathy (CIDP)
    919
  • user avatar
    Sanofi
    @sanofi
    Jun 8
    With the approval from the @EU_Commission, our subcutaneous multiple myeloma (MM) therapy is now authorized across all existing IV indications for MM in the EU. Read more: sanofi.com/en/media-room/…
    Our subcutaneous medicine for patients with multiple myeloma is now approved by the European Commission
    1.2K
  • Sanofi reposted
    user avatar
    VivaTech
    @VivaTech
    May 29
    From discovery to delivery, @sanofi is using #AI to make a real impact🚀 At #VivaTech 2026, see how Sanofi uses AI to deliver faster for patients across R&D, manufacturing & supply & more. Plus, Sanofi & partners will share how AI & quantum tools are driving next‑gen innovation.
    1.3K
  • user avatar
    Sanofi
    @sanofi
    May 28
    #NEWS: The @US_FDA has granted priority review to our new drug application for an investigational oral molecule for type 3 Gaucher disease. Learn more: sanofi.com/en/media-room/…
    The FDA has granted priority review for our investigational oral molecule for type 3 Gaucher disease
    1.1K
  • user avatar
    Sanofi
    @sanofi
    May 18
    Phase 2 data for our investigational treatment for #AATD presented for the first time at #ATS; These findings demonstrate our commitment to advancing innovation for people living with this rare disease. Learn more: sanofi.com/en/media-room/…
    Positive data on AATD shared at ATS 2026 for the first time
    1.2K
  • Sanofi reposted
    user avatar
    VivaTech
    @VivaTech
    May 8
    🔬@sanofi teams are chasing the miracles of science to improve people’s lives. As an R&D‑driven, AI‑powered biopharma company, they’ll show how scaled AI & digital innovation accelerate breakthrough medicines & vaccines for people globally. Find them at #VivaTech 2026🚀
    1.9K
  • user avatar
    Sanofi
    @sanofi
    Apr 24
    #NEWS: The @EMA_News CHMP has recommended for approval our new investigational treatment for secondary progressive #multiplesclerosis without relapses, reinforcing our commitment to advance scientific innovation that address unmet patient needs. Learn more
    Investigational treatment approval recommended for EU approval in SPMS without relapses
    1.7K
  • user avatar
    Sanofi
    @sanofi
    Apr 23
    Our Q1 2026 results are now available. See the press release for more details: spkl.io/6014AfHOC #SanofiResults $SAN $SNY
    2K
  • user avatar
    Sanofi
    @sanofi
    Apr 22
    The @US_FDA has approved our medicine for certain children aged 2-11 years with uncontrolled chronic spontaneous urticaria (CSU). ➡️ Read more: sanofi.com/en/media-room/… CC: @Regeneron
    1.8K
  • user avatar
    Sanofi
    @sanofi
    Apr 22
    The @US_FDA has approved a treatment for eligible young children with #Type1Diabetes. With this approval, we hope to better support these young T1D patients and their families. Learn more: spkl.io/6015A47zl
    Breaking News: FDA approves treatment for eligible young children with T1D. Background shows purple cells. At the bottom is the letter S with a purple dot to the side.
    3K

New to X?

Sign up now to get your own personalized timeline!

Create account

By signing up, you agree to the Terms of Service and Privacy Policy, including Cookie Use.

Terms of Service|Privacy Policy|Cookie Policy|Accessibility|Ads info|© 2026 X Corp.
Don't miss what's happening
People on X are the first to know.
Log inSign up